Legend Biotech’s Post

Last week I presented the first results of the phase 2 ICON study at the European Hematology Association (EHA) conference in Madrid. In the ICON study, relapsed/refractory multiple myeloma patients were treated with iberdomide, low-dose cyclophosphamide and dexamethasone. Iberdomide is a novel cereblon E3 ligase modulator (CELMoD™) with improved direct anti-myeloma activity and immune-stimulatory effects. This treatment regimen resulted in a ORR of 82% and a median PFS of 17.8 months in patients with 2-4 prior lines of therapy. This fully oral, well tolerated, and active combination warrants further evaluation in RRMM. The full abstract is available online: https://lnkd.in/eUqb4Vaq What an interesting conference the #EHA2024 has been! Thanks to all co-authors and my supervisors Niels Van De Donk, Sonja Zweegman and Tuna Mutis.

NEW #Thalassemia Sessions from #ASH23🩸 💬 In this session, leading experts Maria Domenica Cappellini & Kevin Kuo discuss exciting updates in #thalassemia presented at the 2023 ASH Annual Meeting and Exposition The experts cover several topics, including the promise of novel #genetherapies, ongoing #clinicaltrials in the field, and the value of #precisionmedicine 🔬 Take a look 👉 https://lnkd.in/e2-JsM7Y #HemOnc #MPNsm American Society of Hematology

Thanks, Richard! Today, I presented my recent results and insights on transcriptomic MYC activation in CLL. Long story short, high MYC transcriptomic activation is associated with increased interactions with the TME, suggesting MYC as an orchestrator of TME interactions and explaining why it is linked to various cellular processes. #eha #eha2024

Preparing the last details of the podcast interviews to record at the #EHA2024 European Hematology Association congress.

#Congress | 🔎 What subjects were amplified by #HCPs through social media during #EHA2024? In June, took place the European Hematology Association (EHA) 2024 Hybrid Congress. The following pages provide a brief overview of the volume of conversations, the share of voice of clinical trials most discussed, or top hashtags. Moreover, discover a focus on #multiplemyeloma with the topics of discussions. Access the SML EHA2024 full report by clicking this link 👉 https://lnkd.in/e6-MYzHj

We are excited to provide updated clinical safety and efficacy data from 7 transfusion-dependent beta thalassemia patients treated with renizgamglogene autogedtemcel (reni-cel) in the Phase 1/2 EdiThal clinical trial at European Hematology Association (EHA) annual congress. Treated patients had early and robust increases of total hemoglobin (Hb) and fetal hemoglobin, with total Hb rising to or above the transfusion independence threshold of 9.0 g/dL. All patients have been transfusion free for a range of 4.1 to 12.8 months after receiving the last red blood cell transfusion at 0.5–2.2 months post-reni-cel infusion. Reni-cel was well-tolerated and continues to demonstrate a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant. #BetaThalassemia #Biotechnology #Cas12a #CellTherapy #ClinicalTrials #CRISPR #EHA #GeneEditing #Hematology

📢All 12 manuscripts in the #SpecialIssue “#Hematologic #Malignancies: Challenges from Diagnosis to Treatment”, led by Dr. Ioanna Sakellari and Dr. Eleni Gavriilaki, Hematology Department and Dr. Eleni Gavriilaki, have been published! 🎉🎉 📌You are welcome to read via the following link: https://lnkd.in/dyADYnGy

Have you read our recent Q&A with our Reach-the-World Fellow Mark Allan Lim? Learn more about his interest in improving the field of hematology in the Philippines here: https://lnkd.in/eqecTerN

HaemaLogiX Ltd Chief Scientific Officer Dr Rosanne Dunn explains the key highlights of the abstract that was recently published in the European Hematology Association (EHA)’s official open access journal, HemaSphere Journal. Dr Dunn highlights that the data have shown that 100% of amyloidosis patient bone marrow plasma cells express either LMA or KMA. It is also highlighted that LMA and KMA define treatment-resistant, disease-causing plasma cells – in keeping with our published KappaMab Phase 2b clinical results which have also shown that our immunotherapies can deplete these persistent aberrant cells without affecting normal immune cells. Watch the full video below from Dr Dunn on the key highlights of this published data. For more details on this pre-clinical data and its publication, visit our website via this link: https://bit.ly/4b1QgNg

Today we are working at conference EHA-KCS Hematology Tutorial on Recent Advances in Lymphoid and Myeloid Malignancies